Kura Oncology’s Leoni sells 19,009 and 22,241 shares
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Kura Oncology, Inc. Chief Medical Officer Mollie Leoni reported two direct common-stock sales: 19,009 shares on November 16, 2026, at $7.44 per share, and 22,241 shares on November 17, 2026, at a weighted average of $7.45 per share. The November 17 trades ranged from $7.24 to $7.74 per share and were reported as made under a Rule 10b5-1 plan adopted March 19, 2026. The November 16 sale was a sell-to-cover for taxes associated with vesting of performance-based restricted stock units.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock F2, F3 | 22,241 | $7.45 | $166K |
| Sale | Common Stock F1 | 19,009 | $7.44 | $141K |
Footnotes (3)
- F1. Sell-to-cover for taxes associated with the vesting of 1/6th of the underlying shares of performance-based restricted stock units ("PSUs") granted to the Reporting Person on May 31, 2023 and January 2, 2026. Each PSU represents the contingent right to receive one share of the Issuer's common stock based on the achievement of each of three specified development milestones, and the one-year anniversary of each milestone achievement, subject to the Reporting Person's continuous service on each corresponding vesting date. The one-year anniversary of the specified development milestone was determined to be met on November 13, 2026, resulting in the vesting of 1/6th of the underlying shares.
- F2. The shares sold were acquired by the Reporting Person upon vesting of performance restricted stock units on November 13, 2026. The sales reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026.
- F3. This transaction was executed in multiple trades at prices ranging from $7.24 to $7.74. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Key Figures
Key Terms
Rule 10b5-1 trading plan regulatory
performance-based restricted stock units financial
sell-to-cover financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.